AIMS: Baseline adiponectin concentrations predict incident Type 2 diabetes mellitus in the Diabetes Prevention Program. We tested the hypothesis that common variants in the genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1, ADIPOR2) would associate with circulating adiponectin concentrations and/or with diabetes incidence in the Diabetes Prevention Program population. METHODS:Seventy-seven tagging single-nucleotide polymorphisms (SNPs) in ADIPOQ (24), ADIPOR1 (22) and ADIPOR2 (31) were genotyped. Associations of SNPs with baseline adiponectin concentrations were evaluated using linear modelling. Associations of SNPs with diabetes incidence were evaluated using Cox proportional hazards modelling. RESULTS: Thirteen of 24 ADIPOQ SNPs were significantly associated with baseline adiponectin concentrations. Multivariable analysis including these 13 SNPs revealed strong independent contributions of rs17366568, rs1648707, rs17373414 and rs1403696 with adiponectin concentrations. However, no ADIPOQ SNPs were directly associated with diabetes incidence. Two ADIPOR1 SNPs (rs1342387 and rs12733285) were associated with ∼18% increased diabetes incidence for carriers of the minor allele without differences across treatment groups, and without any relationship with adiponectin concentrations. CONCLUSIONS: ADIPOQ SNPs are significantly associated with adiponectin concentrations in the Diabetes Prevention Program cohort. This observation extends prior observations from unselected populations of European descent into a broader multi-ethnic population, and confirms the relevance of these variants in an obese/dysglycaemic population. Despite the robust relationship between adiponectin concentrations and diabetes risk in this cohort, variants in ADIPOQ that relate to adiponectin concentrations do not relate to diabetes risk in this population. ADIPOR1 variants exerted significant effects on diabetes risk distinct from any effect of adiponectin concentrations.
RCT Entities:
AIMS: Baseline adiponectin concentrations predict incident Type 2 diabetes mellitus in the Diabetes Prevention Program. We tested the hypothesis that common variants in the genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1, ADIPOR2) would associate with circulating adiponectin concentrations and/or with diabetes incidence in the Diabetes Prevention Program population. METHODS: Seventy-seven tagging single-nucleotide polymorphisms (SNPs) in ADIPOQ (24), ADIPOR1 (22) and ADIPOR2 (31) were genotyped. Associations of SNPs with baseline adiponectin concentrations were evaluated using linear modelling. Associations of SNPs with diabetes incidence were evaluated using Cox proportional hazards modelling. RESULTS: Thirteen of 24 ADIPOQ SNPs were significantly associated with baseline adiponectin concentrations. Multivariable analysis including these 13 SNPs revealed strong independent contributions of rs17366568, rs1648707, rs17373414 and rs1403696 with adiponectin concentrations. However, no ADIPOQ SNPs were directly associated with diabetes incidence. Two ADIPOR1 SNPs (rs1342387 and rs12733285) were associated with ∼18% increased diabetes incidence for carriers of the minor allele without differences across treatment groups, and without any relationship with adiponectin concentrations. CONCLUSIONS:ADIPOQ SNPs are significantly associated with adiponectin concentrations in the Diabetes Prevention Program cohort. This observation extends prior observations from unselected populations of European descent into a broader multi-ethnic population, and confirms the relevance of these variants in an obese/dysglycaemic population. Despite the robust relationship between adiponectin concentrations and diabetes risk in this cohort, variants in ADIPOQ that relate to adiponectin concentrations do not relate to diabetes risk in this population. ADIPOR1 variants exerted significant effects on diabetes risk distinct from any effect of adiponectin concentrations.
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Frank B Hu; Alessandro Doria; Tricia Li; James B Meigs; Simin Liu; Asli Memisoglu; David Hunter; JoAnn E Manson Journal: Diabetes Date: 2004-01 Impact factor: 9.461
Authors: F Vasseur; N Helbecque; S Lobbens; V Vasseur-Delannoy; C Dina; K Clément; P Boutin; T Kadowaki; P E Scherer; P Froguel Journal: Diabetologia Date: 2005-04-14 Impact factor: 10.122
Authors: Barbora Vozarova de Courten; Robert L Hanson; Tohru Funahashi; Robert S Lindsay; Yuji Matsuzawa; Sachiyo Tanaka; Farook Thameem; Jonathan D Gruber; Philippe Froguel; Johanna K Wolford Journal: Diabetes Date: 2005-01 Impact factor: 9.461
Authors: Jennifer R Rider; Michelangelo Fiorentino; Rachel Kelly; Travis Gerke; Kristina Jordahl; Jennifer A Sinnott; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci; Stephen Finn Journal: Carcinogenesis Date: 2015-04-11 Impact factor: 4.944
Authors: Hanieh Yaghootkar; Claudia Lamina; Robert A Scott; Zari Dastani; Marie-France Hivert; Liling L Warren; Alena Stancáková; Sarah G Buxbaum; Leo-Pekka Lyytikäinen; Peter Henneman; Ying Wu; Chloe Y Y Cheung; James S Pankow; Anne U Jackson; Stefan Gustafsson; Jing Hua Zhao; Christie M Ballantyne; Weijia Xie; Richard N Bergman; Michael Boehnke; Fatiha el Bouazzaoui; Francis S Collins; Sandra H Dunn; Josee Dupuis; Nita G Forouhi; Christopher Gillson; Andrew T Hattersley; Jaeyoung Hong; Mika Kähönen; Johanna Kuusisto; Lyudmyla Kedenko; Florian Kronenberg; Alessandro Doria; Themistocles L Assimes; Ele Ferrannini; Torben Hansen; Ke Hao; Hans Häring; Joshua W Knowles; Cecilia M Lindgren; John J Nolan; Jussi Paananen; Oluf Pedersen; Thomas Quertermous; Ulf Smith; Terho Lehtimäki; Ching-Ti Liu; Ruth J F Loos; Mark I McCarthy; Andrew D Morris; Ramachandran S Vasan; Tim D Spector; Tanya M Teslovich; Jaakko Tuomilehto; Ko Willems van Dijk; Jorma S Viikari; Na Zhu; Claudia Langenberg; Erik Ingelsson; Robert K Semple; Alan R Sinaiko; Colin N A Palmer; Mark Walker; Karen S L Lam; Bernhard Paulweber; Karen L Mohlke; Cornelia van Duijn; Olli T Raitakari; Aurelian Bidulescu; Nick J Wareham; Markku Laakso; Dawn M Waterworth; Debbie A Lawlor; James B Meigs; J Brent Richards; Timothy M Frayling Journal: Diabetes Date: 2013-07-08 Impact factor: 9.461
Authors: Kirsten E Peters; John Beilby; Gemma Cadby; Nicole M Warrington; David G Bruce; Wendy A Davis; Timothy Me Davis; Steven Wiltshire; Matthew Knuiman; Brendan M McQuillan; Lyle J Palmer; Peter L Thompson; Joseph Hung Journal: BMC Med Genet Date: 2013-01-25 Impact factor: 2.103